AI assistant
Merck & Co., Inc. — Director's Dealing 2018
Feb 8, 2018
284_dirs_2018-02-08_61e2bcfd-ee28-4629-afa4-a89048a7b6d9.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 5 — Annual Statement of Changes in Beneficial Ownership
Issuer: OPGEN INC (OPGN)
CIK: 0001293818
Period of Report: 2017-12-31
Reporting Person: Merck & Co., Inc. (10% Owner)
Reporting Person: Merck Sharp & Dohme Corp. (10% Owner)
Reporting Person: Merck Global Health Innovation Fund, LLC (10% Owner)
Derivative Transactions
| Date | Security | Exercise Price | Code | Shares | A/D | Expiration | Underlying | Ownership |
|---|---|---|---|---|---|---|---|---|
| 2017-06-28 | Warrant to Purchase Common Stock | $19.50 | A | 13120 | Acquired | 2022-06-28 | Common Stock (13120) | Indirect |
Footnotes
F1: These amounts reflect the Issuer's recently announced and effectuated a 1 for 25 reverse stock split on January 17, 2018.
F2: These securities are owned directly by Merck Global Health Innovation Fund, LLC ("MGHIF"), which is a wholly owned subsidiary of Merck Sharp & Dohme Corp. ("MSD"), which is a wholly owned subsidiary of Merck & Co., Inc. ("Merck"). MSD and Merck are indirect beneficial owners of the reported securities.